Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis
Tal Burstyn-Cohen, … , Mary Jo Heeb, Greg Lemke
Tal Burstyn-Cohen, … , Mary Jo Heeb, Greg Lemke
Published September 1, 2009
Citation Information: J Clin Invest. 2009;119(10):2942-2953. https://doi.org/10.1172/JCI39325.
View: Text | PDF
Research Article Vascular biology

Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis

  • Text
  • PDF
Abstract

Protein S (ProS) is a blood anticoagulant encoded by the Pros1 gene, and ProS deficiencies are associated with venous thrombosis, stroke, and autoimmunity. These associations notwithstanding, the relative risk that reduced ProS expression confers in different disease settings has been difficult to assess without an animal model. We have now described a mouse model of ProS deficiency and shown that all Pros1–/– mice die in utero, from a fulminant coagulopathy and associated hemorrhages. Although ProS is known to act as a cofactor for activated Protein C (aPC), plasma from Pros1+/– heterozygous mice exhibited accelerated thrombin generation independent of aPC, and Pros1 mutants displayed defects in vessel development and function not seen in mice lacking protein C. Similar vascular defects appeared in mice in which Pros1 was conditionally deleted in vascular smooth muscle cells. Mutants in which Pros1 was deleted specifically in hepatocytes, which are thought to be the major source of ProS in the blood, were viable as adults and displayed less-severe coagulopathy without vascular dysgenesis. Finally, analysis of mutants in which Pros1 was deleted in endothelial cells indicated that these cells make a substantial contribution to circulating ProS. These results demonstrate that ProS is a pleiotropic anticoagulant with aPC-independent activities and highlight new roles for ProS in vascular development and homeostasis.

Authors

Tal Burstyn-Cohen, Mary Jo Heeb, Greg Lemke

×

Figure 9

Elimination of ProS from hepatocytes in adult Alb-Cre/Pros1fl/fl mice and EC contribution of ProS to the circulation.

Options: View larger image (or click on image) Download as PowerPoint
Elimination of ProS from hepatocytes in adult Alb-Cre/Pros1fl/fl mice an...
(A) Immunoblots of ProS (top) and β-actin (bottom) of protein extracts of purified hepatocytes prepared from WT, Alb-Cre/Pros1fl/+, and Alb-Cre/Pros1fl/fl adult mice. Alb-Cre/Pros1fl/+ and Alb-Cre/Pros1fl/fl lanes were run on the same gel but were noncontiguous. (B) ELISA measurements of serum ProS levels in individual adult (8 weeks or older) mice of the indicated genotypes. (See Methods for ELISA/antibody protocols.) Levels in individual mice are expressed as a percentage of the mean value of measurements from 17 different wild-type mice (Combined WT). Mean values and P values for comparisons between wild-type, EIIA-Cre/Pros1fl/+ heterozygous, and Alb-Cre/Pros1fl/fl and tie2-Cre/Pros1fl/fl homozygous sera are indicated. HC, hepatocytes. (C) Measurement of aPC cofactor activity (prolongation of clotting time in seconds) in plasmas from mice of the indicated genotypes, in assays performed as those in Figure 5A (see Methods), expressed as percentage of WT. Mean values and P values for comparisons between heterozygous Alb-Cre/Pros1fl/+, Tie2-Cre/Pros1fl/+, and WT plasmas are indicated. Mean prolongation of clot time by aPC in WT mice (54.8 seconds) was taken as 100% aPC cofactor activity of ProS.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts